In an effort to make Risk Evaluation and Mitigation Strategies (REMS) easier to share and integrate with current health information and pharmacy systems, the U.S. Food and Drug Administration (FDA) announced a four-month pilot to begin the transitioning process. REMS are strategies that manage known or potential serious risks associated with a medication, thereby allowing patients access to a treatment that serves an unmet need. The project will run from October 6, 2015 through February 3, 2016 with the FDA currently accepting applications from interested parties through December 7, 2015. Read more here.
Last Updated on May 7, 2020 by Aimed Alliance
